Tirzepatide — 10 mg

Description

Tirzepatide is a synthetic peptide that acts biochemically as a dual agonist at the GIP and GLP-1 receptors, originated by Eli Lilly. It has been approved and marketed as a pharmaceutical (Mounjaro, Zepbound) and is supplied here solely as a lyophilized research chemical.

Research context: In published laboratory and preclinical research, tirzepatide has been studied in the context of incretin (GIP and GLP-1) receptor signaling and metabolic-regulation pathways.

Specifications: Molecular mass 4813.45 Da; CAS 2023788-19-2; purity ≥98% (HPLC); 10 mg lyophilized powder in a sealed vial; storage −20°C (24 months).

This product is supplied strictly for in-vitro laboratory research. It is not a drug, food, cosmetic, or dietary supplement, and is not intended for human or animal consumption, medical, veterinary, or household use.